Inhibikase Therapeutics, Inc. Retained Earnings
Inhibikase Therapeutics, Inc. (IKT) had Retained Earnings of -$178.65 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-11
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$178.65M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$159.06M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$142.68M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$129.95M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | -$178.65M 10-Q · filed 2026-08-11 | |
| 2026-03-31 | -$159.06M 10-Q · filed 2026-05-12 | |
| 2025-12-31 | -$142.68M 10-Q · filed 2026-08-11 | |
| 2025-09-30 | -$129.95M 10-Q · filed 2025-11-14 | |
| 2025-06-30 | -$118.01M 10-Q · filed 2025-08-14 | |
| 2025-03-31 | -$108.10M 10-Q · filed 2025-05-14 | |
| 2024-12-31 | -$94.42M 10-K · filed 2026-03-26 | |
| 2024-09-30 | -$82.29M 10-Q · filed 2024-11-14 | |
| 2024-06-30 | -$76.51M 10-Q · filed 2024-08-14 | |
| 2024-03-31 | -$71.55M 10-Q · filed 2024-05-15 | |
| 2023-12-31 | -$66.90M 10-K · filed 2025-03-27 | |
| 2023-09-30 | -$62.72M 10-Q · filed 2023-11-14 | |
| 2023-06-30 | -$58.13M 10-Q · filed 2023-08-14 | |
| 2023-03-31 | -$52.35M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | -$47.87M 10-K · filed 2024-03-27 | |
| 2022-09-30 | -$43.59M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | -$39.10M 10-Q · filed 2022-08-12 | |
| 2022-03-31 | -$34.46M 10-Q · filed 2022-05-16 | |
| 2021-12-31 | -$29.82M 10-K · filed 2023-03-31 | $29.82M 10-K · filed 2022-03-31 |
| 2021-09-30 | -$24.78M 10-Q · filed 2021-11-15 | |
| 2021-06-30 | -$20.30M 10-Q · filed 2021-08-16 | |
| 2021-03-31 | -$17.67M 10-Q · filed 2021-05-17 | |
| 2020-12-31 | $15.03M 10-K · filed 2022-03-31 | -$15.03M 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |